- Home
- MQY vs CDNA Comparison
MQY vs CDNA Comparison
Compare MQY & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- CDNA
- Stock Information
- Founded
- MQY 1994
- CDNA 1998
- Country
- MQY United States
- CDNA United States
- Employees
- MQY N/A
- CDNA N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- CDNA Medical Specialities
- Sector
- MQY Finance
- CDNA Health Care
- Exchange
- MQY Nasdaq
- CDNA Nasdaq
- Market Cap
- MQY 784.4M
- CDNA 844.7M
- IPO Year
- MQY N/A
- CDNA 2014
- Fundamental
- Price
- MQY $11.19
- CDNA $16.25
- Analyst Decision
- MQY
- CDNA Buy
- Analyst Count
- MQY 0
- CDNA 7
- Target Price
- MQY N/A
- CDNA $30.33
- AVG Volume (30 Days)
- MQY 184.8K
- CDNA 1.2M
- Earning Date
- MQY 01-01-0001
- CDNA 04-30-2025
- Dividend Yield
- MQY 4.73%
- CDNA N/A
- EPS Growth
- MQY N/A
- CDNA N/A
- EPS
- MQY N/A
- CDNA 1.07
- Revenue
- MQY N/A
- CDNA $346,421,000.00
- Revenue This Year
- MQY N/A
- CDNA $13.37
- Revenue Next Year
- MQY N/A
- CDNA $15.28
- P/E Ratio
- MQY N/A
- CDNA $15.23
- Revenue Growth
- MQY N/A
- CDNA 25.92
- 52 Week Low
- MQY $9.82
- CDNA $7.42
- 52 Week High
- MQY $12.52
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- MQY 52.84
- CDNA 44.83
- Support Level
- MQY $11.22
- CDNA $14.09
- Resistance Level
- MQY $11.43
- CDNA $18.71
- Average True Range (ATR)
- MQY 0.11
- CDNA 0.97
- MACD
- MQY 0.05
- CDNA 0.01
- Stochastic Oscillator
- MQY 64.92
- CDNA 44.16
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.